Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.
Read Full NewsPrograms offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.
Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.
A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.
1.
How AI will transform mental health support for patients with breast cancer
2.
US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry
3.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
4.
New imaging probe helps track prostate cancer and possibly treat it before resistance develops
5.
Radioiodine therapy found to improve relative survival rates of differentiated thyroid cancer patients
1.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
2.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
5.
Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
3.
Navigating the Complexities of Ph Negative ALL - Part VIII
4.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
5.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge